EDI-M408

EDI-M408 is a preclinical-stage small molecule inhibitor developed by the Empire Discovery Institute. It is designed to target Interleukin-1 receptor-associated kinase 4 (IRAK4) and Interleukin-1 receptor-associated kinase 1 (IRAK1), which are key components of the Myddosome complex. This complex plays a critical role in signaling downstream of Toll-like receptors (TLRs) and Interleukin-1 receptors (IL-1Rs), pathways that are frequently dysregulated in various malignancies. By inhibiting the kinase activity of both IRAK4 and IRAK1, EDI-M408 aims to disrupt pro-survival and pro-proliferative signaling in cancer cells. The drug is currently being investigated for its potential in treating oncology indications, specifically acute myeloid leukemia (AML) and various solid tumors.